Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
0.570
+0.068 (13.51%)
Nov 7, 2024, 4:00 PM EST - Market closed
Unicycive Therapeutics Employees
Unicycive Therapeutics had 14 employees as of December 31, 2023. The number of employees increased by 2 or 16.67% compared to the previous year.
Employees
14
Change (1Y)
2
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,743,286
Market Cap
53.76M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 14 | 2 | 16.67% |
Dec 31, 2022 | 12 | 3 | 33.33% |
Dec 31, 2021 | 9 | 8 | 800.00% |
Dec 31, 2020 | 1 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Allurion Technologies | 504 |
Fortress Biotech | 186 |
HOOKIPA Pharma | 179 |
Accelerate Diagnostics | 134 |
OncoCyte | 46 |
CalciMedica | 12 |
VYNE Therapeutics | 10 |
Anebulo Pharmaceuticals | 3 |
UNCY News
- 10 days ago - Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - GlobeNewsWire
- 22 days ago - Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 - GlobeNewsWire
- 24 days ago - Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 - GlobeNewsWire
- 4 weeks ago - Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers - GlobeNewsWire
- 6 weeks ago - Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - GlobeNewsWire
- 7 weeks ago - Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 - GlobeNewsWire
- 2 months ago - Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - GlobeNewsWire